Delving into the Latest Updates on Hangzhou Shengyu Biomedical Technology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Urogenital Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	8
Endocrinology and Metabolic Disease	2

Top 5 Drug Type	Count

Small molecule drug	6
Chemical drugs	2

Top 5 Target	Count

PARG(Poly(ADP-ribose) glycohydrolase)	2
POLQ(DNA polymerase theta)	2

一项评价SYN818（一种DNA聚合酶θ[POLQ]抑制剂）与奥拉帕利联合给药在携带乳腺癌易感基因（BRCA）突变和/或同源重组修复（HRR）通路缺陷的局部晚期或转移性实体瘤患者中的安全性、耐受性、药代动力学和初步抗肿瘤活性的Ib期研究

[Translation] A Phase Ib study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of SYN818, a DNA polymerase theta [POLQ] inhibitor, in combination with olaparib in patients with locally advanced or metastatic solid tumors harboring breast cancer susceptibility gene (BRCA) mutations and/or homologous recombination repair (HRR) pathway deficiencies.

评价SYN818与奥拉帕利联合给药在携带BRCA突变和/或HRR通路缺陷的局部晚期或转移性实体瘤受试者中的安全性和耐受性，可能包括确定最大耐受剂量（MTD）和/或II期推荐剂量（RP2D），以及评价SYN818与奥拉帕利联合给药的初步疗效。

[Translation]

To evaluate the safety and tolerability of SYN818 in combination with olaparib in subjects with locally advanced or metastatic solid tumors harboring BRCA mutations and/or HRR pathway defects. This may include determining the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D), as well as evaluating the preliminary efficacy of the SYN818 in combination with olaparib.

Start Date-

Sponsor / Collaborator

Hangzhou Shengyu Biomedical Technology Co., Ltd.

100 Clinical Results associated with Hangzhou Shengyu Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Hangzhou Shengyu Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Hangzhou Shengyu Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Hangzhou Shengyu Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

2

Preclinical

IND Application

1

2

Phase 1

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

SYN818 ( POLQ )	Locally Advanced Malignant Solid Neoplasm More	Phase 1
SYN608 ( PARG )	Locally Advanced Malignant Solid Neoplasm More	Phase 1
SY-001	Solid tumor More	IND Application
SYX-1097 ( POLQ )	Neoplasms More	Preclinical
SYX3759 ( PARG )	Neoplasms More	Preclinical